HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03759379 |
|
Recruitment Status :
Active, not recruiting
First Posted : November 30, 2018
Last Update Posted : February 11, 2021
|
Sponsor:
Alnylam Pharmaceuticals
Information provided by (Responsible Party):
Alnylam Pharmaceuticals
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of vutrisiran (ALN-TTRSC02) in patients with hereditary transthyretin amyloidosis (hATTR amyloidosis). Participants will receive vutrisiran or the reference comparator patisiran during the Treatment Period. The Treatment Period is followed by a Treatment Extension Period during which all participants in the patisiran group will switch to vutrisiran. This study will use the placebo arm of the APOLLO study (NCT01960348) as an external comparator for the primary and most other efficacy endpoints.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Amyloidosis, Hereditary Transthyretin Amyloidosis | Drug: Patisiran Drug: Vutrisiran (ALN-TTRSC02) | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 164 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) |
| Actual Study Start Date : | February 14, 2019 |
| Actual Primary Completion Date : | November 10, 2020 |
| Estimated Study Completion Date : | May 2024 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Transthyretin amyloidosis
MedlinePlus related topics:
Amyloidosis
Drug Information available for:
Patisiran
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Vutrisiran (ALN-TTRSC02)
Participants will receive vutrisiran during the Treatment and Treatment Extension Periods.
|
Drug: Vutrisiran (ALN-TTRSC02)
Vutrisiran will be administered by subcutaneous (SC) injection. |
|
Active Comparator: Patisiran
Participants will receive patisiran during the Treatment Period and will switch to vutrisiran during the Treatment Extension Period.
|
Drug: Patisiran
Patisiran will be administered by intravenous (IV) infusion. Drug: Vutrisiran (ALN-TTRSC02) Vutrisiran will be administered by subcutaneous (SC) injection. |
Primary Outcome Measures :
- Change from Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 [ Time Frame: Baseline, Month 9 ]The mNIS+7 is a composite score that quantifies motor, sensory, and autonomic neurologic impairment due to injury of large and small nerves. The minimum and maximum values are 0 and 304, respectively. A higher score indicates a worse outcome.
Secondary Outcome Measures :
- Change from Baseline in Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) Total Score at Month 9 [ Time Frame: Baseline, Month 9 ]The Norfolk QoL-DN questionnaire is a standardized 35-item patient-reported outcomes measure that is sensitive to the different features of diabetic neuropathy - small fiber, large fiber, and autonomic nerve function. The minimum and maximum values are -4 and 136, respectively. A higher score indicates a worse outcome.
- Change from Baseline in the Timed 10-Meter Walk Test (10-MWT) at Month 9 [ Time Frame: Baseline, Month 9 ]
- Change from Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 18 [ Time Frame: Baseline, Month 18 ]The mNIS+7 is a composite score that quantifies motor, sensory, and autonomic neurologic impairment due to injury of large and small nerves. The minimum and maximum values are 0 and 304, respectively. A higher score indicates a worse outcome.
- Change from Baseline in Norfolk QoL-DN Total Score at Month 18 [ Time Frame: Baseline, Month 18 ]The Norfolk QoL-DN questionnaire is a standardized 35-item patient-reported outcomes measure that is sensitive to the different features of diabetic neuropathy - small fiber, large fiber, and autonomic nerve function. The minimum and maximum values are -4 and 136, respectively. A higher score indicates a worse outcome.
- Change from Baseline in the 10-MWT at Month 18 [ Time Frame: Baseline, Month 18 ]
- Change from Baseline in the Modified Body Mass Index (mBMI) at Month 18 [ Time Frame: Baseline, Month 18 ]
- Change from Baseline in the Rasch-Built Overall Disability Scale (R-ODS) at Month 18 [ Time Frame: Baseline, Month 18 ]The R-ODS is comprised of a 24-item linearly weighted scale that specifically captures activity and social participation limitations. The minimum and maximum values are 0 and 48, respectively. A higher score indicates a better outcome.
- Percentage Reduction in Serum Transthyretin (TTR) Levels Through Month 18 [ Time Frame: Up to Month 18 ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 85 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male or female of 18 to 85 years of age (inclusive);
- Has a diagnosis of hATTR amyloidosis with transthyretin (TTR) mutation;
- Has adequate neurologic impairment score (NIS);
- Has adequate polyneuropathy disability (PND) score;
- Has adequate Karnofsky Performance Status (KPS).
Exclusion Criteria:
- Had a prior liver transplant or is likely to undergo liver transplantation during the study;
- Has known other (non-hATTR) forms of amyloidosis or leptomeningeal amyloidosis;
- Has New York Heart Association heart failure classification >2;
- Clinically significant liver function test abnormalities;
- Has known human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV) infection;
- Received an experimental drug within 30 days of dosing;
- Received prior TTR-lowering treatment;
- Has other known causes of neuropathy.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03759379
Locations
Show 55 study locations
Sponsors and Collaborators
Alnylam Pharmaceuticals
Investigators
| Study Director: | Medical Director | Alnylam Pharmaceuticals |
| Responsible Party: | Alnylam Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT03759379 |
| Other Study ID Numbers: |
ALN-TTRSC02-002 2018-002098-23 ( EudraCT Number ) |
| First Posted: | November 30, 2018 Key Record Dates |
| Last Update Posted: | February 11, 2021 |
| Last Verified: | February 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Amyloid Neuropathies, Familial Amyloidosis, Familial Amyloidosis Proteostasis Deficiencies Metabolic Diseases Heredodegenerative Disorders, Nervous System Neurodegenerative Diseases |
Nervous System Diseases Amyloid Neuropathies Peripheral Nervous System Diseases Neuromuscular Diseases Genetic Diseases, Inborn Metabolism, Inborn Errors |